Wang et al. (2022) evaluated the prognostic value of VM-related genes and demonstrated that VM may be a potential target for evaluating immunotherapy in gastric cancer. Previous studies confirmed the regulatory effects of ARHGAP25, RhoA, PP2A, MMP2, and sema4D on VM based on lung cancer cells (Li et al., 2017; Xia et al., 2019; Shi et al., 2022; Zhang et al., 2022), suggesting the involvement of these molecules in the VM formation process. The gene discussed is ARHGAP25; the disease is gastric cancer.